Cargando…

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2

INTRODUCTION: The availability of mice transgenic for the human HER2 gene (huHER2) and prone to the development of HER2-driven mammary carcinogenesis (referred to as FVB-huHER2 mice) prompted us to study active immunopreventive strategies targeting the human HER2 molecule in a tolerant host. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Giovanni, Carla, Nicoletti, Giordano, Quaglino, Elena, Landuzzi, Lorena, Palladini, Arianna, Ianzano, Marianna Lucia, Dall’Ora, Massimiliano, Grosso, Valentina, Ranieri, Dario, Laranga, Roberta, Croci, Stefania, Amici, Augusto, Penichet, Manuel L, Iezzi, Manuela, Cavallo, Federica, Nanni, Patrizia, Lollini, Pier-Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979148/ https://www.ncbi.nlm.nih.gov/pubmed/24451168 http://dx.doi.org/10.1186/bcr3602

Ejemplares similares

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013)

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
por: Palladini, Arianna, et al.
Publicado: (2017)

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R
por: De Giovanni, Carla, et al.
Publicado: (2019)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Giusti, Veronica, et al.
Publicado: (2021)

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas
por: Landuzzi, Lorena, et al.
Publicado: (2014)

Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(−/−);Il2rg(−/−) Mice and Treatment with PI3K Inhibitor
por: Nanni, Patrizia, et al.
Publicado: (2012)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
por: De Giovanni, Carla, et al.
Publicado: (2021)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
por: Landuzzi, Lorena, et al.
Publicado: (2021)

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
por: De Giovanni, Carla, et al.
Publicado: (2019)

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model
por: De Giovanni, Carla, et al.
Publicado: (2019)

Virus-like particle display of HER2 induces potent anti-cancer responses
por: Palladini, Arianna, et al.
Publicado: (2018)

Prevention and Therapy of Metastatic HER-2(+) Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice
por: Nanni, Patrizia, et al.
Publicado: (2001)

Interleukin 12–mediated Prevention of Spontaneous Mammary Adenocarcinomas in Two Lines of Her-2/neu Transgenic Mice
por: Boggio, Katia, et al.
Publicado: (1998)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis
por: Macagno, Marco, et al.
Publicado: (2022)

Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer
por: Jacca, Sarah, et al.
Publicado: (2015)

Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.
por: Nanni, P., et al.
Publicado: (1996)

DNA vaccination against oncoantigens: A promise
por: Iezzi, Manuela, et al.
Publicado: (2012)

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice
por: Bandini, Silvio, et al.
Publicado: (2013)

Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
por: Marchini, Cristina, et al.
Publicado: (2013)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination.
por: Nicoletti, G., et al.
Publicado: (1992)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells.
por: De Giovanni, C., et al.
Publicado: (1993)

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
por: Nanni, Patrizia, et al.
Publicado: (2019)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

HER2-Displaying M13 Bacteriophages induce Therapeutic Immunity against Breast Cancer
por: Wang, Junbiao, et al.
Publicado: (2022)

Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin.
por: De Giovanni, C., et al.
Publicado: (1995)

The Promise of Preventive Cancer Vaccines
por: Lollini, Pier-Luigi, et al.
Publicado: (2015)

HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells
por: Zhang, Yi, et al.
Publicado: (2009)

Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status
por: Soares, Maria, et al.
Publicado: (2016)

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tg125fodu3m0q0gftqv5ktmlgk